Ontario Drug Benefit (ODB) Formulary / Comparative Drug Index (Formulary) has been updated and becomes effective February 28, 2017.
New Single Source Drug Products
Daklinza (daclatasvir) 30mg, 60mg Tab (BMS)
Epclusa (sofosbuvir / velpatasvir) 400mg/100mg Tab (GIL)
Sunvepra (asunaprevir) 100mg Tab (BMS)
Zepatier (elbasvir / grazoprevir) 50mg/100mg Tab (MEK)
Transition from Exceptional Access Program (EAP) to Limited Use (LU)
Ibavyr (ribavirin) 200mg, 400mg, 600mg Tab (PEN)
Sovaldi (sofosbuvir) 400mg Tab (GIL)
Harvoni (ledipasvir / sofosbuvir) 90mg/400mg Tab (GIL)
To receive updates similar to this one please be sure to sign up for Market Access Signals, our free e-mail newsletter service.